Sunovion Pharmaceuticals Inc.'s $635 million buy of Cynapsus Therapeutics Inc. gained new validation with the success of a pivotal phase III trial testing the object of the deal, a sublingual version of the antiparkinsonian drug apomorphine. Read More
Bridgebio Pharma Inc.'s asset hunter Michael Henderson told BioWorld his firm "came a bit late in the game" when attempting to grab a phase II cancer asset that Novartis AG no longer wanted, but officials "burned some nights and weekends" to win. Read More
Still haunted by the deadly negligence of the New England Compounding Center (NECC), a House Energy and Commerce subcommittee checked the pulse Tuesday of how the FDA is implementing the Compounding Quality Act that was passed to give the agency more oversight of drug compounders. Read More
January set a new record for biopharmaceutical public financings tracked over the last 18 years, with a more than 20 percent increase in the value of follow-on offerings over the second highest January three years ago. Read More
LONDON – The first release of data from the World Health Organization's (WHO) new global antimicrobial surveillance system reveals high levels of resistance to a number of serious bacterial infections in both high and low income countries. Read More
HONG KONG – Less than two months after picking up a big win with the FDA approval for Mylan NV-partnered Herceptin biosimilar Ogivri (trastuzumab-dkst), India's Biocon Ltd. inked a deal with another leader in biosimilar development, Sandoz Inc., a division of Novartis AG, to develop, manufacture and commercialize multiple products in the areas of immunology and oncology. Read More
A new genomics system developed to identify interferon-sensitive mutations was used to generate an attenuated hyper-interferon (IFN)-susceptible influenza virus vaccine candidate, which not only elicited robust immune responses but could also be used to produce vaccines against other pathogens, Chinese and U.S. researchers reported in the Jan. 19, 2018, edition of Science. Read More
Amarin Corp. plc, of Dublin, priced an underwritten public offering of its American depositary shares (ADSs) for gross proceeds of approximately $70 million and granted the underwriter a 30-day option to purchase approximately $10.5 million in additional ADSs. Read More
Biomx Ltd., of Ness Ziona, Israel, said it exclusively sublicensed from JSR Corp., of Tokyo, a set of bacterial targets for the development and commercialization of phage therapies that eradicate such targets to treat inflammatory bowel disease (IBD). Read More
Alteogen lnc., of Daejeon, South Korea, dosed the first patient in a phase I trial testing ALT-P7, a HER2-targeting antibody-drug conjugate developed with the company's Nexmab technology, in 42 patients with advanced or recurrent HER2 positive metastatic breast cancer that is not amenable to the current standard therapy. Read More
